Benzinga | Mar 2, 2021 01:21PM EST

Stifel Initiates Coverage On Fulcrum Therapeutics with Buy Rating, Announces Price Target of $18

Stifel analyst Dae Gon Ha initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Buy rating and announces Price Target of $18.